Abscess https://en.wikipedia.org/wiki/Abscess
Abscess jẹ akojọpọ pus ti o ti gbe soke laarin awọn ara ti ara. Awọn ami ati awọn aami aiṣan ti abscesses pẹlu pupa, irora, igbona, ati wiwu. Wiwu naa le ni ito‑kún nigba titẹ. Agbegbe ti pupa nigbagbogbo n lọ kọja agbegbe ti wiwu.

Wọn maa n fa nipasẹ ikolu kokoro‑arun. Kokoro arun ti o wọpọ julọ ti o wa ni Staphylococcus aureus (methicillin‑resistant). Ayẹwo ti abscess awọ‑ara ni a maa n ṣe da lori ohun ti o dabi ati pe a fi idi rẹ mulẹ nipasẹ gige ati ṣiṣan. Aworan olutirasandi le jẹ iwulo ninu awọn ọran ninu eyiti ayẹwo ko han. Ni abscesses ni ayika anus, kọmputa tomography (CT) le jẹ pataki lati wa fun jinle ikolu.

Itọju deede fun awọ ara pupọ julọ tabi awọn abscesses tissu rirọ jẹ gige ati ṣiṣan lakoko lilo awọn egboogi. Gbigbe pus jade pẹlu abẹrẹ nigbagbogbo ko to.

Awọn abscesses awọ‑ara jẹ wọpọ ati pe o ti di diẹ sii ni awọn ọdun aipẹ. Awọn okunfa eewu pẹlu lilo oogun inu iṣọn, pẹlu awọn oṣuwọn royin bi giga bi 65 % laarin awọn olumulo. Ni ọdun 2005 ni Ilu Amẹrika, eniyan miliọnu 3.2 lọ si ẹka pajawiri fun absẹsi (abscess). Ni ilu Ọstrelia, awọn eniyan 13,000 wa ni ile‑iwosan ni ọdun 2008 pẹlu ipo naa.

Itọju
Atọju abscesses pẹlu lori‑ni‑counter oloro jẹ soro ni ọpọlọpọ igba. Ti awọn aami aisan bii ìbà (fever) ati otutu ba han ni gbogbo ara, jọwọ kan si dokita kan ni kete bi o ti ṣee.

Alaye siwaju sii ― Yoruba
References Current Treatment Options for Acute Skin and Skin-structure Infections 30957166 
NIH
Ọpọlọpọ eniyan lọ si awọn yara pajawiri fun awọn akoran awọ ara (abscess) ti o fa nipasẹ awọn kokoro arun. Staphylococcus aureus ni kokoro akọkọ ti o fa awọn akoran wọnyi, ati pe o nira pupọ lati tọju nitori ifarahan community-associated methicillin-resistant Staphylococcus aureus (MRSA).
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
 Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus 32257966 
NIH
Staphylococcus aureus le pin si oriṣi meji ti o da lori idahun wọn si awọn oogun ajesara (antibiotic): methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). Ni awọn ọdun diẹ sẹhin, nitori itankalẹ kokoro arun ati ilokulo awọn oogun ajesara (antibiotic), ilodisi ti S. aureus si awọn oogun ti n pọ si, ti o yori si ilosoke agbaye ni awọn oṣuwọn ikolu MRSA.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
 Treatment of severe skin and soft tissue infections: a review 29278528 
NIH
To review the salient features of the management of severe skin and soft tissue infections (SSTIs), including toxic shock syndrome, myonecrosis/gas gangrene, and necrotizing fasciitis.